Allergan Targets Sandoz Over Generic Latisse

Law360, New York (April 18, 2011, 5:28 PM EDT) -- Allergan Inc. launched a patent infringement suit Friday in a North Carolina federal court over Sandoz Inc.’s efforts to manufacture a generic version of Latisse, a treatment to stimulate eyelash growth.

Allergan and Duke University allege that Sandoz’s abbreviated new drug application seeking permission to manufacture bimatoprost ophthalmic solution infringes three patents. The suit marks Allergan’s latest efforts to protect Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers desiring longer or thicker lashes....
To view the full article, register now.